| Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity J Palazuelos, T Aguado, MR Pazos, B Julien, C Carrasco, E Resel, ... Brain 132 (11), 3152-3164, 2009 | 425 | 2009 |
| Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? J Fernández‐Ruiz, O Sagredo, MR Pazos, C García, R Pertwee, ... British journal of clinical pharmacology 75 (2), 323-333, 2013 | 413 | 2013 |
| Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease C Blazquez, A Chiarlone, O Sagredo, T Aguado, MR Pazos, E Resel, ... Brain 134 (1), 119-136, 2011 | 232 | 2011 |
| Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease O Sagredo, S González, I Aroyo, MR Pazos, C Benito, I Lastres‐Becker, ... Glia 57 (11), 1154-1167, 2009 | 211 | 2009 |
| A restricted population of CB1 cannabinoid receptors with neuroprotective activity A Chiarlone, L Bellocchio, C Blázquez, E Resel, E Soria-Gómez, ... Proceedings of the National Academy of Sciences 111 (22), 8257-8262, 2014 | 185 | 2014 |
| Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A … O Sagredo, JA Ramos, A Decio, R Mechoulam, J Fernández‐Ruiz European Journal of Neuroscience 26 (4), 843-851, 2007 | 168 | 2007 |
| Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice S Valdeolivas, C Navarrete, I Cantarero, ML Bellido, E Muñoz, O Sagredo Neurotherapeutics 12, 185-199, 2017 | 155 | 2017 |
| Role of CB2 receptors in neuroprotective effects of cannabinoids J Fernández-Ruiz, MR Pazos, M García-Arencibia, O Sagredo, JA Ramos Molecular and cellular endocrinology 286 (1-2), S91-S96, 2008 | 153 | 2008 |
| A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease JL López-Sendón Moreno, J García Caldentey, P Trigo Cubillo, ... Journal of neurology 263, 1390-1400, 2016 | 143 | 2016 |
| Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy MJ Casarejos, J Perucho, A Gomez, MP Munoz, M Fernandez-Estevez, ... Journal of Alzheimer's Disease 35 (3), 525-539, 2013 | 133 | 2013 |
| Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease O Sagredo, MR Pazos, V Satta, JA Ramos, RG Pertwee, ... Journal of neuroscience research 89 (9), 1509-1518, 2011 | 123 | 2011 |
| Cannabinoids and neuroprotection in basal ganglia disorders O Sagredo, M García-Arencibia, E De Lago, S Finetti, A Decio, ... Molecular neurobiology 36, 82-91, 2007 | 118 | 2007 |
| Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors S Valdeolivas, V Satta, RG Pertwee, J Fernández-Ruiz, O Sagredo ACS chemical neuroscience 3 (5), 400-406, 2012 | 116 | 2012 |
| Cannabinoids: novel medicines for the treatment of Huntington's disease O Sagredo, M Ruth Pazos, S Valdeolivas, J Fernández-Ruiz Recent Patents on CNS Drug Discovery (Discontinued) 7 (1), 41-48, 2012 | 115 | 2012 |
| The endocannabinoid system as a target for the treatment of neuronal damage J Fernández-Ruiz, C García, O Sagredo, M Gómez-Ruiz, E de Lago Expert opinion on therapeutic targets 14 (4), 387-404, 2010 | 114 | 2010 |
| The endocannabinoid system in Huntington's disease MR Pazos, O Sagredo, J Fernandez-Ruiz Current pharmaceutical design 14 (23), 2317-2325, 2008 | 99 | 2008 |
| Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats EM Romero, B Fernández, O Sagredo, N Gomez, L Urigüen, C Guaza, ... Developmental brain research 136 (2), 85-92, 2002 | 94 | 2002 |
| The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of … S Valdeolivas, MR Pazos, T Bisogno, F Piscitelli, FA Iannotti, M Allara, ... Cell death & disease 4 (10), e862-e862, 2013 | 86 | 2013 |
| Possible therapeutic applications of cannabis in the neuropsychopharmacology field J Fernández-Ruiz, I Galve-Roperh, O Sagredo, M Guzmán European Neuropsychopharmacology 36, 217-234, 2020 | 44 | 2020 |
| New Serotonin 5-HT1A Receptor Agonists with Neuroprotective Effect against Ischemic Cell Damage I Marco, M Valhondo, M Martı́n-Fontecha, H Vazquez-Villa, J Del Rı́o, ... Journal of medicinal chemistry 54 (23), 7986-7999, 2011 | 44 | 2011 |
Javier Fernández-RuizProfesor de Bioquímica, Universidad ComplutenseVerified email at ucm.es
